Currently, the only Food and Drug Administration-approved predictive biomarkers of ICI response are programmed death-ligand (PD-L1) expression for specific cancers and microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) for a tumour-agnostic indication. This evidence concerns the gene CD274 and cancer.